Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
With
Sanofi
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or female 18 to 65 years of age.
Weight\> 50 kg and \<95 kg inclusive
For men of childbearing potential, willingness to utilize adequate contraception and not have their partner\[s\] become pregnant during the full duration of the study.
Willing, committed, and able to return for all clinic visits and complete all study-related procedures.
Able to read, understand and willing to sign the informed consent form.
You may not be if
Initiation of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to screening visit.
Women of childbearing potential, pregnant and breast-feeding women are excluded. Women are considered to be of childbearing potential until they have been amenorrheic for at least 12 months or have had surgical sterilization.
Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the subject's participation in this study.
Hospitalization for any reason within 60 days of screening.
Known history of Human Immunodeficiency Virus (HIV) antibody; and/or positive Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the screening visit.
Previous exposure to any therapeutic or investigational biological agent.
History of alcohol or substance abuse within a year prior to the screening visit.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers
